Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01096862 · ClinicalTrials.gov registry record · Phase 2
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
A Phase 2 study of Psoriasis, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
- 11
- Study locations
NCT01096862 is a Phase 2 study of Psoriasis that has completed, run by Astellas Pharma. The registered enrollment target is 124 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (75% lower). The trial reports 11 study locations across 10 states.
The verdict
NCT01096862, a Phase 2 study of Psoriasis, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to explore the efficacy and safety of multiple, escalating doses of ASP015K when compared to placebo in subjects with moderate to severe plaque psoriasis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG peficitinib
Study Locations (11)
Florida
- FXM Research, Corp. - Miami
- Renstar Medical Research - Ocala
Alabama
- Total Skin & Beauty Dermatology Center - Birmingham
California
- Therapeutics Clinical Research - San Diego
Kentucky
- Derm Research, PLLC - Louisville
Oregon
- Oregon Medical Research Center - Portland
South Carolina
- Palmetto Clinical Trial Services - Greenville
Tennessee
- Rivergate Dermatology - Goodlettsville
Texas
- J & S Studies - College Station
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2010-03-23 |
| Est. Completion | 2011-07-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01096862
The ClinicalTrials.gov registry entry for NCT01096862 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (75% lower). The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01096862 reports 11 study locations spanning 10 distinct geographic areas - top geographies include Florida, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT01096862 about?
NCT01096862 is a clinical study titled "A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis". The purpose of this study is to explore the efficacy and safety of multiple, escalating doses of ASP015K when compared to placebo in subjects with moderate to severe plaque psoriasis.
What is the current status of trial NCT01096862?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2010-03-23. Estimated completion is 2011-07-27.
What conditions does trial NCT01096862 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT01096862?
The interventions under investigation include: Placebo (DRUG), peficitinib (DRUG).
Who is sponsoring clinical trial NCT01096862?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01096862 being conducted?
This trial has 11 study locations across Alabama, California, Florida, Kentucky, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study in Participants With Moderate to Severe Psoriasis
COMPLETED · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
COMPLETED · Phase 2
-
Etanercept With Tacrolimus for Psoriasis
COMPLETED · Phase 2
-
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.